[3H]spiperone binding to lymphocyte in extrapyramidal disease and in aging.
[3H]Spiperone binding to lymphocytes in Parkinson's disease (PD), Wilson's disease (WD), and age-matched control groups was studied. In the untreated PD group, [3H]spiperone binding was lower than in young controls, but did not differ from elderly healthy persons. After treatment with levodopa, the number of [3H]spiperone binding sites increased. In WD, lower binding of [3H]spiperone compared with age-matched controls was found. However, the magnitude of the differences in [3H]spiperone binding to lymphocytes in PD was too small to permit its use as a routine indicator of the disease state or the adequacy of pharmacological treatment in individual patients. [3H]Spiperone binding to lymphocytes decreases with age. Changes in [3H]spiperone binding to lymphocytes may be a general phenomenon for all states where dopamine is depleted, including normal aging. The nature of [3H]spiperone binding to lymphocytes remains unclear. The possible influence of dopamine on immune reactivity is discussed.
Członkowska
A
A
Institute of Psychiatry and Neurology, Medical Academy, Warsaw, Poland.
Jachowicz-Jeszka
J
J
Członkowski
A
A
D000328:Adult; D000368:Aged; D000375:Aging / Q000378:metabolism*; D000978:Antiparkinson Agents / Q000627:therapeutic use; D005260:Female; D006527:Hepatolenticular Degeneration / Q000378:metabolism*; D006801:Humans; D008214:Lymphocytes / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy / Q000378:metabolism*; D011954:Receptors, Dopamine / Q000378:metabolism*; D017448:Receptors, Dopamine D2; D012016:Reference Values; D013134:Spiperone / Q000378:metabolism*
D000978:Antiparkinson Agents; D011954:Receptors, Dopamine; D017448:Receptors, Dopamine D2; D013134:Spiperone